Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Advanced Breast Cancer
Related studies linked through entity extraction aliases.
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
- Status
- RECRUITING
- Phase
- PHASE2
New Model for Integrating Person-based Care (PbC) in the Treatment of Advanced HER2-negative Breast Cancer
- Status
- UNKNOWN
- Phase
- N/A
A Biomarker Screening Protocol for Participants With Solid Tumors
- Status
- TERMINATED
- Phase
- N/A
Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- NA
Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)
- Status
- RECRUITING
- Phase
- PHASE3
RC48-ADC in HER2-low Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- NA
PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)
- Status
- UNKNOWN
- Phase
- PHASE3
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment
- Status
- COMPLETED
- Phase
- PHASE4
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor
- Status
- RECRUITING
- Phase
- PHASE2
Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2